Living Donors Online Message Board
Living Donation Discussion and News => Living Donation in the News => Topic started by: Clark on May 08, 2017, 01:08:14 PM
-
http://jasn.asnjournals.org/content/28/1/12.abstract?sid=fd52aef1-1734-40a3-add7-b4423e6fddae (http://jasn.asnjournals.org/content/28/1/12.abstract?sid=fd52aef1-1734-40a3-add7-b4423e6fddae)
Understanding and Communicating Medical Risks for Living Kidney Donors: A Matter of Perspective
Krista L. Lentine (http://jasn.asnjournals.org/search?author1=Krista+L.+Lentine&sortspec=date&submit=Submit)*† and Dorry L. Segev (http://jasn.asnjournals.org/search?author1=Dorry+L.+Segev&sortspec=date&submit=Submit)‡§
September 2, 2016, doi: 10.1681/ASN.2016050571
JASN January 2017 vol. 28 no. 1 12-24
Abstract
Communicating the current knowledge of medical outcomes after live kidney donation necessary to support donor candidates in well informed decision-making requires grounding in perspectives of comparison. Baseline risk (without donating), risk attributable to donation, and absolute risk (after donating) need to be considered. Severe perioperative complications and death are rare, but vary by demographic, clinical, and procedure factors. Innovative capture of “healthy” controls designed to simulate donor selection processes has identified higher risk of ESRD attributable to donation in two studies; importantly, however, the absolute 15-year ESRD incidence in donors remains very low (0.3%). In the first decade after donation, the risk of all-cause mortality and cardiovascular events is no higher than in healthy nondonors. Pregnancies in donors may incur attributable risk of gestational hypertension or preeclampsia (11% versus 5% incidence in one study). A modest rise in uric acid levels beginning early after donation, and a small (1.4%) increase in the 8-year incidence of gout, have also been reported in comparisons to healthy nondonors. As in the general population, postdonation outcomes vary by race, sex, and age. Efforts to improve the counseling and selection of living donors should focus on developing tools for tailored risk prediction according to donor characteristics, and ideally, compared with similar healthy nondonors.